LOC728369 Inhibitors
LOC728369 inhibitors encompass a diverse group of chemical compounds that exert their inhibitory effects through various cellular and biochemical pathways, ultimately leading to the downregulation of LOC728369's functional activity. Compounds such as Palmitoyl-DL-carnitine and N-Ethylmaleimide work by interfering with mitochondrial functions and inactivating cysteine proteases, respectively, which can influence LOC728369 activity given its potential association with these processes. Proteasome inhibitors like MG132, Lactacystin, Bortezomib, and Epoxomicin contribute to the accumulation of polyubiquitinated proteins, potentially saturating LOC728369's deubiquitinating capabilities and thus indirectly inhibiting its function. Additionally, LY294002 and U0126, inhibitors of the PI3K/AKT and MEK/ERK pathways, respectively, may decrease LOC728369 activity by disrupting signaling pathways that LOC728369 is thought to be involved in, particularly in relation to cell cycle regulation and response to cellular stressors.
Furthermore, SB203580, SP600125, and Z-LEHD-FMK target different components of stress and apoptotic signaling pathways, such as p38 MAPK, JNK, and caspase-9, which could lead to an indirectreduction of LOC728369 activity if it participates in the modulation of these pathways. For example, inhibition of JNK by SP600125 could hinder LOC728369's involvement in stress signaling, while Z-LEHD-FMK's inhibition of caspase-9 might stabilize substrates that LOC728369 would otherwise process. Oxidative state modulators like glutathione, in its oxidized form, may alter the redox-sensitive aspects of LOC728369's function, assuming it has any redox-regulated activity. These inhibitors, through their distinct mechanisms, collectively contribute to the attenuation of LOC728369's activity by impacting the protein's direct or indirect interactions with various cellular pathways, including those related to ubiquitination, metabolism, and intracellular signaling.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that leads to the inhibition of the AKT signaling pathway. Since LOC728369 may play a role in cell cycle regulation and AKT pathway is crucial for this process, inhibition of this pathway can indirectly decrease the activity of LOC728369. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can lead to an accumulation of polyubiquitinated proteins. This can potentially saturate LOC728369, rendering it less effective in its deubiquitinating functions. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor that prevents the degradation of ubiquitinated proteins, which could indirectly inhibit LOC728369 by reducing its substrate availability. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that disrupts the MAPK/ERK pathway. If LOC728369 is involved in the regulation of this pathway, inhibition by U0126 could reduce LOC728369 activity indirectly by altering the signaling environment. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could indirectly affect LOC728369 by altering the stress response pathways in which USP17L24 may be involved, thereby reducing its functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that may impede the function of LOC728369 if it is involved in JNK-related stress or apoptotic signaling pathways, leading to an indirect decrease in LOC728369 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that, by preventing the breakdown of polyubiquitinated proteins, may indirectly inhibit LOC728369 by reducing the availability of its substrates. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin specifically inhibits the proteasome's chymotrypsin-like activity, which could reduce the functional activity of LOC728369 by limiting the degradation of ubiquitin-conjugated proteins. | ||||||
caspase-9 inhibitor I | 210345-04-3 | sc-3085 sc-3085A | 1 mg 5 mg | $416.00 $1769.00 | 33 | |
Z-LEHD-FMK is a caspase-9 inhibitor that, if LOC728369 is involved in caspase-regulated apoptosis pathways, could indirectly inhibit LOC728369 by stabilizing proteins that would otherwise be deubiquitinated. | ||||||
N-Ethylmaleimide | 128-53-0 | sc-202719A sc-202719 sc-202719B sc-202719C sc-202719D | 1 g 5 g 25 g 100 g 250 g | $22.00 $69.00 $214.00 $796.00 $1918.00 | 19 | |
N-Ethylmaleimide is a sulfhydryl-reactive compound that could inactivate cysteine proteases and potentially affect the cysteine-dependent isopeptidase activity of LOC728369. | ||||||